Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Diluted EPS of $1.80 per share for fiscal year 2025.
BIOMARIN PHARMACEUTICAL INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $1.80 | -18.6% |
| 2024 | $2.21 | +154.0% |
| 2023 | $0.87 | +16.0% |
| 2022 | $0.75 | +314.3% |
| 2021 | -$0.35 | -107.8% |
| 2020 | $4.50 | +3561.5% |
| 2019 | -$0.13 | +70.5% |
| 2018 | -$0.44 | +34.3% |
| 2017 | -$0.67 | +82.4% |
| 2016 | -$3.81 | -256.1% |
| 2015 | -$1.07 | -16.3% |
| 2014 | -$0.92 | +3.2% |
| 2012 | -$0.95 | -97.9% |
| 2011 | -$0.48 | -127.7% |
| 2010 | $1.73 | — |
| 2009 | $0.00 | -100.0% |
| 2008 | $0.29 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.16 | -129.1% | -113.0% |
| June 30, 2025 | $1.23 | +123.6% | +29.5% |
| March 31, 2025 | $0.95 | +106.5% | +72.7% |
| September 30, 2024 | $0.55 | +161.9% | +0.0% |
| June 30, 2024 | $0.55 | +89.7% | +19.6% |
| March 31, 2024 | $0.46 | +70.4% | +119.0% |
| September 30, 2023 | $0.21 | +625.0% | -27.6% |
| June 30, 2023 | $0.29 | +93.3% | +7.4% |
- BIOMARIN PHARMACEUTICAL INC showed a decrease of -18.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2008–2025 period, BIOMARIN PHARMACEUTICAL INC’s diluted eps has grown by 520.7% (from $0.29 per share to $1.80 per share).
- The most recent figure is from BIOMARIN PHARMACEUTICAL INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: